>
Acrux logo

ACR - Acrux Share Price

A$0.155 0.0  0.0%

Last Trade - 1:01am

Sector
Healthcare
Size
Micro Cap
Market Cap £14.6m
Enterprise Value £9.47m
Revenue £2.32m
Position in Universe 1404th / 1893
Bullish
Bearish
Unlock ACR Revenue
Momentum
Relative Strength (%)
1m -1.01%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -51.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
25.2 28.6 23.9 3.43 5.29 3.95 -31.0%
-60.2 +16.6 -48.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, AcruxLimited revenues increased 39% to A$800K. Net lossincreased 21% to A$7.8M. Revenues reflect Australia segmentincrease from A$140K to A$376K, United States segmentincrease of 11% to A$40K. Higher net loss reflects Externalresearch and development expens increase of 88% to A$4.6M(expense), Share options expense increase from A$134K toA$303K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ACR Revenue Unlock ACR Revenue

Net Income

ACR Net Income Unlock ACR Revenue

Normalised EPS

ACR Normalised EPS Unlock ACR Revenue

PE Ratio Range

ACR PE Ratio Range Unlock ACR Revenue

Dividend Yield Range

ACR Dividend Yield Range Unlock ACR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ACR EPS Forecasts Unlock ACR Revenue
Profile Summary

Acrux Limited is a drug development company. The Company is engaged in developing and commercializing branded and generic transdermal and topical pharmaceuticals for global markets. The Company's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The Company's products include Axiron, Ellavie, Evamist and Lenzetto. Axiron (testosterone) topical solution CIII is a testosterone topical solution approved for application via an armpit (underarm) applicator. It has developed the estradiol spray for women, used to treat moderate to severe hot flushes commonly associated with menopause. In the United States, the Company's estradiol spray is branded Evamist. The Company has licensed its estradiol product to Gedeon Richter to commercialize in various territories, including Europe and Eurasia. Gedeon Richter has branded the estradiol spray as Lenzetto.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated March 19, 1998
Public Since September 29, 2004
No. of Shareholders: 5,557
No. of Employees: 43
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 168,583,515
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ACR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ACR
Upcoming Events for ACR
Frequently Asked Questions for Acrux
What is the Acrux share price?

As of 1:01am, shares in Acrux are trading at A$0.155, giving the company a market capitalisation of £14.6m. This share price information is delayed by 15 minutes.

How has the Acrux share price performed this year?

Shares in Acrux are currently trading at A$0.155 and the price has moved by 6.9% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Acrux price has moved by -19.83% over the past year.

What are the analyst and broker recommendations for Acrux?

Of the analysts with advisory recommendations for Acrux, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Acrux is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Acrux next release its financial results?

Acrux is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Acrux dividend yield?

Acrux does not currently pay a dividend.

Does Acrux pay a dividend?

Acrux does not currently pay a dividend.

When does Acrux next pay dividends?

Acrux does not currently pay a dividend.

How do I buy Acrux shares?

To buy shares in Acrux you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Acrux?

Shares in Acrux are currently trading at A$0.155, giving the company a market capitalisation of £14.6m.

Where are Acrux shares listed? Where are Acrux shares listed?

Here are the trading details for Acrux:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: ACR
What kind of share is Acrux?

Based on an overall assessment of its quality, value and momentum, Acrux is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Acrux share price forecast 2021?

Shares in Acrux are currently priced at A$0.155. At that level they are trading at 49.68% discount to the analyst consensus target price of 0.00.

How can I tell whether the Acrux share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acrux. Over the past six months, the relative strength of its shares against the market has been -24.68%. At the current price of A$0.155, shares in Acrux are trading at -9.38% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Acrux PE Ratio?

We were not able to find PE ratio data for Acrux.

Who are the key directors of Acrux?

Acrux's management team is headed by:

Ross Dobinson - NEC
Timothy Oldham - NID
Michael Kotsanis - CEO
Felicia Colagrande - OTH
Geoffrey Brooke - NID
Charles O'Sullivan - OTH
Deborah Ambrosini - CFO
Norman Gray - NED
Who are the major shareholders of Acrux?

Here are the top five shareholders of Acrux based on the size of their shareholding:

Phillip Asset Management Limited Investment Advisor
Percentage owned: 11.28% (31.8m shares)
Samuel Terry Asset Management Pty Ltd Investment Advisor
Percentage owned: 3.62% (10.2m shares)
DDH Graham Limited Investment Advisor
Percentage owned: 3.46% (9.77m shares)
MNM Capital Pty. Ltd. Corporation
Percentage owned: 1.61% (4.56m shares)
Dobinson (Ross) Individual Investor
Percentage owned: 1.14% (3.23m shares)
Similar to ACR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.